GRTS Investors Have Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit

Core Viewpoint - Gritstone bio, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its business operations and the launch of its COVID-19 vaccine candidate [3][6][7]. Group 1: Allegations and Impact - The lawsuit claims that Gritstone made false and/or misleading statements about its ability to launch the Phase 2b CORAL Study within the timeframe promised to investors [3]. - It is alleged that Gritstone's inability to launch the study would impair its ability to secure external funding, negatively affecting its balance sheet and cash position [3]. - The lawsuit asserts that Gritstone overstated its capability to successfully develop and commercialize its products, leading to materially false and misleading public statements [3]. Group 2: Class Action Details - Shareholders who purchased Gritstone securities between March 9, 2023, and February 29, 2024, are eligible to participate in the class action [6]. - The deadline for filing a motion to be appointed as lead plaintiff is August 6, 2024 [2][6]. - Investors do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [2].